Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Dec 10, 2023
Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month. Companies operating in this sector, such as Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT), have all contributed to this impressive performance.

🌐Tickers in Industry - $NBIX, $ACAD, $ALKS, $MDXG, $CYCCP, $VCEL, $VTGN, $MRNA 

Choppy Market Trader, Popular Stocks: Market Neutral Strategy (TA&FA)Ā -Ā Annualized Return + 107%

Theme and Group of Tickers Inside the Theme

The theme in focus here is the installation industry, with a specific emphasis on companies engaged in manufacturing home products and items related to home improvement. The notable tickers within this theme include:

  1. Masco Corp. (MAS): Specializes in building and home improvement products.
  2. Installed Building Products Inc. (FIX): Primarily involved in insulation installer operations.
  3. nVent Electric plc. (NVT): Specializes in electrical connections.

Market Cap

The average market capitalization for companies within the installation theme is approximately $5.6 billion. However, there is significant variation within this group, with market caps ranging from $52.3 million to $13.4 billion. Masco Corp. (MAS) holds the highest valuation at $13.4 billion, while the lowest valued company is KEQU at $52.3 million.

High and Low Price Notable News

In the past month, stocks within the installation theme have experienced substantial price movements. On average, these stocks have seen a remarkable monthly price growth of 19.6%. The average weekly price growth was 6.44%, and the average quarterly price growth was 25.83%.

Notable price movements in this theme include Masco Corp. (MAS) witnessing a significant weekly decline of -5.16% and, in contrast, a weekly gain of +5.43%. nVent Electric (NVT) also saw a notable weekly gain of +5.79%, reflecting the volatility and potential for substantial returns in this sector.

Volume

The trading volumes for stocks in the installation theme have exhibited some interesting trends. On average, there was a weekly volume decrease of -4.76% in the past month, while the monthly and quarterly volume trends showed even more significant declines of -34.01% and -16.5%, respectively.

It's worth noting that nVent Electric's stock witnessed a remarkable daily volume growth of 99% of the 65-Day Volume Moving Average on August 1, 2023. Similarly, Griffon stock experienced a one-day volume surge, reaching a growth of 296% of the 65-Day Volume Moving Average on June 17, 2023.

Fundamental Analysis Ratings

While specific fundamental analysis ratings are not provided in the information given, it's clear that the installation industry, particularly in the residential segment, is exhibiting strong performance. The impressive monthly price growth of 19.6% underscores the sector's potential for investors seeking growth opportunities.

The installation industry, encompassing companies involved in home improvement and related products, has shown outstanding stock performance over the past month. Investors should take note of the opportunities presented by stocks like Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT) in this thriving sector.

NBIXĀ :Ā On November 24, 2023, NBIX exhibited a noteworthy shift in its trajectory as it crossed above its 50-day Moving Average. Historically, such occurrences have often translated into positive momentum, with 32 out of 39 comparable instances resulting in subsequent price increases over the following month. With an 82% probability, the odds appear favorable for NBIX to sustain its upward trajectory. Investors may find this development an encouraging sign for potential gains in the near future.

ACADĀ :Ā ACAD Pharmaceuticals recently exhibited a notable shift in its stock trajectory, breaching its 50-day Moving Average on December 5, 2023. This movement signifies a potential reversal from its previous upward momentum to a bearish trend. Historical analysis reveals that in 35 out of 45 comparable scenarios, ACAD's stock experienced further decline in the subsequent month. This pattern suggests a 78% probability of the stock continuing its downward trend. Investors and market analysts are closely monitoring this development, considering its implications for future investment strategies and market positioning related to ACAD.

ALKSĀ :Ā ALKS Pharmaceuticals exhibited a significant shift in market sentiment as its Momentum Indicator ascended above the zero mark on November 16, 2023. This transition is widely interpreted as a precursor to a new upward trend in the stock's performance. Investors and traders are advised to consider strategies like purchasing shares or opting for call options in anticipation of potential gains. Tickeron's A.I.dvisor analyzed 95 comparable events where the indicator turned positive. In 76 of these instances, ALKS's stock price increased in the subsequent period, indicating an 80% likelihood of a continued upward movement. This trend presents a promising opportunity for market participants focusing on ALKS.

Ā 

Related Ticker: NBIX, ACAD, ALKS, MDXG, BGMSP, VCEL, VTGN, MRNA

NBIX in +4.02% Uptrend, advancing for three consecutive days on July 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Aroon Indicator entered an Uptrend today. In of 275 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

NBIX moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NBIX crossed bearishly below the 50-day moving average on August 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBIX broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.198) is normal, around the industry mean (40.756). P/E Ratio (22.297) is within average values for comparable stocks, (94.098). Projected Growth (PEG Ratio) (0.451) is also within normal values, averaging (2.238). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (4.679) is also within normal values, averaging (177.108).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.12B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 31%. AMLX experienced the highest price growth at 79%, while AKAN experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 82
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
6027 Edgewood Bend Court
Phone
+1 858 617-7600
Employees
2000
Web
https://www.neurocrine.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillipsĀ (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.